niftify.in

The Economic Times

Ipca launches new topical therapy against diabetic foot ulcer

Ipca Laboratories introduced Diulcus, a topical gel designed to treat diabetic foot ulcers, priced at Rs 1365 per pack. The gel is based on repurposed beta blocker Esmolol. Approved after clinical trials, the product showed promising ulcer closure rates, with Ipca targeting a substantial market share within three years.

Mint

IPCA Laboratories Q1 Results Live: profit rise by 18.07% YOY

IPCA Laboratories Q1 Results Live: Revenue increased by 31.81% YoY & profit increased by 18.07% YoY

Business Standard

Ipca Labs Q1 results: Net profit up 18% at Rs 192 cr on robust sales

Ipca Laboratories on Tuesday said its consolidated net profit increased 18 per cent to Rs 192 crore for the first quarter ended June 30, 2024 aided by robust sales in the domestic market. The drug firm had reported a net profit of Rs 163 crore for the April-June period of last fiscal. Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The drug firm said domestic formulations income rose 12 per cent year-on-year to Rs 873 crore in the first quarter. Exports income, however, declined 4 per cent year-on-year to Rs 591 crore during the June quarter, the company said. Shares of Ipca Laboratories on Tuesday closed 1.33 per cent up at Rs 1,400 apiece on the BSE.

Business Line

Movers & Shakers: Stocks that will see action this week

Here is what the charts say about the shares of Gujarat Gas, Ipca Laboratories and LTIMindtree